Overview

Human IgGs and Endothelial Function in Vivo in Humans

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:
0

Participant gender:
All

Summary

Endothelial dysfunction and insulin resistance play a key role in the onset and development of atherosclerosis, cardiovascular diseases, and diabetes. Data in mice models have recently demonstrated that circulating immunoglobulins G (IgG) could be involved in the process. Patients with common variable immunodeficiency (CVID), who are characterized by low circulating levels of IgG, might represent an ideal model to clarify the role played in vivo in humans by circulating IgG. Polyclonal IgG, obtained from multiple donors, given intravenously (IVIgG), are used to treat various immunodeficiencies and autoimmune diseases, including CVID. By using this disease and its treatment by IVIgG as a model, aim of the current study is to clarify whether IgG affect endothelial function and insulin sensitivity in humans in vivo and whether the action of IgG on the endothelium involves a direct interaction with the endothelial cells.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Federico II University

Treatments:

Antibodies
Immunoglobulin G
Immunoglobulins

Criteria

Inclusion Criteria:

- Common Variable Immunodeficiency

Exclusion Criteria:

- Cancer, liver Cirrhosis, recent acute myocardial infarction, treatment with
nitroderivates, Reynaud syndrome, heart failure